Xencor Inc. Stock
Xencor Inc. Stock
A loss of -1.670% shows a downward development for Xencor Inc..
We see a rather positive sentiment for Xencor Inc. with 14 Buy predictions and 2 Sell predictions.
As a result the target price of 22 € shows a very positive potential of 86.44% compared to the current price of 11.8 € for Xencor Inc..
Pros and Cons of Xencor Inc. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xencor Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xencor Inc. | -1.670% | -4.762% | -16.667% | -45.946% | -5.512% | -51.220% | -69.849% |
| Ironwood Pharmaceuticals | 2.380% | -7.182% | 7.006% | -23.636% | 26.316% | -68.356% | -65.361% |
| Novocure Ltd | 0.770% | 14.171% | 9.802% | -52.333% | 12.660% | -85.794% | -90.872% |
| Iovance Biotherapeutics Inc. | -5.370% | -2.096% | 9.900% | -66.279% | -11.404% | -63.286% | -95.001% |
Comments
Xencor (NASDAQ:XNCR) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $26.00 price target on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) had its price target raised by analysts at Royal Bank Of Canada from $18.00 to $19.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
News
Xencor (XNCR) Q2 Revenue Jumps 82%
Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company’s GAAP
